Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,687 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR.
Kokalaki E, Ma B, Ferrari M, Grothier T, Hazelton W, Manzoor S, Costu E, Taylor J, Bulek A, Srivastava S, Gannon I, Jha R, Gealy R, Stanczuk L, Rizou T, Robson M, El-Kholy M, Baldan V, Righi M, Sillibourne J, Thomas S, Onuoha S, Cordoba S, Pule M. Kokalaki E, et al. Among authors: ma b. Mol Ther. 2024 Feb 7;32(2):556-558. doi: 10.1016/j.ymthe.2023.12.006. Epub 2023 Dec 15. Mol Ther. 2024. PMID: 38103549 Free article. No abstract available.
Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR.
Kokalaki E, Ma B, Ferrari M, Grothier T, Hazelton W, Manzoor S, Costu E, Taylor J, Bulek A, Srivastava S, Gannon I, Jha R, Gealy R, Stanczuk L, Rizou T, Robson M, El-Kholy M, Baldan V, Righi M, Sillibourne J, Thomas S, Onuoha S, Cordoba S, Pule M. Kokalaki E, et al. Among authors: ma b. Mol Ther. 2023 Jul 5;31(7):2089-2104. doi: 10.1016/j.ymthe.2023.03.020. Epub 2023 Mar 21. Mol Ther. 2023. PMID: 36945773 Free PMC article.
Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies.
Ferrari M, Righi M, Baldan V, Wawrzyniecka P, Bulek A, Kinna A, Ma B, Bughda R, Akbar Z, Srivastava S, Gannon I, Robson M, Sillibourne J, Jha R, El-Kholy M, Amin OM, Kokalaki E, Banani MA, Hussain R, Day W, Lim WC, Ghongane P, Hopkins JR, Jungherz D, Herling M, Welin M, Surade S, Dyson M, McCafferty J, Logan D, Cordoba S, Thomas S, Sewell A, Maciocia P, Onuoha S, Pule M. Ferrari M, et al. Among authors: ma b. Nat Commun. 2024 Feb 21;15(1):1583. doi: 10.1038/s41467-024-45854-3. Nat Commun. 2024. PMID: 38383515 Free PMC article.
Rice transcription factor bHLH25 confers resistance to multiple diseases by sensing H2O2.
Liao H, Fang Y, Yin J, He M, Wei Y, Zhang J, Yong S, Cha J, Song L, Zhu X, Chen X, Kováč J, Hou Q, Ma Z, Zhou X, Chen L, Yumoto E, Yang T, He Q, Li W, Deng Y, Li H, Li M, Qing H, Zou L, Bi Y, Liu J, Yang Y, Ye D, Tao Q, Wang L, Xiong Q, Lu X, Tang Y, Li T, Ma B, Qin P, Li Y, Wang W, Qian Y, Ďurkovič J, Miyamoto K, Chern M, Li S, Li W, Wang J, Chen X. Liao H, et al. Among authors: ma b. Cell Res. 2025 Jan 14. doi: 10.1038/s41422-024-01058-4. Online ahead of print. Cell Res. 2025. PMID: 39806170
First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer.
Lakhani NJ, Stewart D, Richardson DL, Dockery LE, Van Le L, Call J, Rangwala F, Wang G, Ma B, Metenou S, Huguet J, Offman E, Pandite L, Hamilton E. Lakhani NJ, et al. Among authors: ma b. J Immunother Cancer. 2025 Jan 11;13(1):e010565. doi: 10.1136/jitc-2024-010565. J Immunother Cancer. 2025. PMID: 39800375 Clinical Trial.
6,687 results